A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis ...

Emactuzumab has received fast track designation from the U.S. FDA for patients with tenosynovial giant cell tumors and who would not benefit from surgery. Treatment with emactuzumab has received fast ...

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...

"Our stem cell-based cell culture system is a valuable model to study viral infections," says Carpentier. "The cells are almost identical to primary liver cells and therefore offer more realistic ...

Researchers have discovered a giant coral colony on the north-western coast of Saudi Arabia, in a part of the Red Sea that is being developed as a luxury tourist resort. The colony, a feature ...

Cars driving past the Kennedy Center witnessed an unexpected liftoff on Thursday, after a 30-foot-tall Mars balloon escaped its moorings and rolled from its place outside the arts center onto the ...

Microsoft researchers claim they’ve developed the largest-scale 1-bit AI model, also known as a “bitnet,” to date. Called BitNet b1.58 2B4T, it’s openly available under an MIT license and ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.